Managment of vaginal bleeding by ayurvedic medicine and procedure

Phase 2

Completed

• Conditions: Abnormal uterine and vaginal bleeding, unspecified,

• Registration Number: CTRI/2020/03/023744
• Lead Sponsor: IPGT AND RA GAU JAMNAGAR

Brief Summary

This wasan open-labelled, comparative parallel-group study in the management of *Asrigdara*.In this trial total of 38 patients were enrolled, 34 patients completed thetreatment, and follow-up, 4 patients were dropped out. In Group A 17 patients had been prescribed *Virechana*and*VasadiChurna*3 gm 6 hourly during*bleeding*and 3gmBDafter bleeding and in Group B, 17 patients had been prescribedthe *Vasadi Churna 3gm 6 hourly during bleeding and 3gm BD afterbleeding for 60 days.* After the completion of the treatment protocol,the follow-up period was 1 month for both groups to assess the difference in the consecutivemenstrual cycle. The assessment was done based on signsand symptoms i.e., Excessive Bleeding, Prolonged durationbleeding, Intermenstrual Bleeding, Bleeding with clots and associatedcomplaints like *Vedana, Angamarda, Panduta, Daurbalya, Daha,Bhrama.*

**Results:**In the Overall effect of therapy, percentage relief in Group A was89.30% while in Group B it was 74.93%. In Group A 47.05% of patients got completeremission and 35.30% of patients were found to marked improvement. While 17.65%were found to moderate improvement, no patient was found Mild improvement andremained unchanged. In Group B 5.88% of patients got complete remission and41.17% of patients found marked improvement. While 47.05% of patients gotmoderate improvement, 5.88% got Mild improvement and no patient remainedunchanged. This data shows that *Virechana with Vasadi Churna*Group(Group A) is better than *Vasadi Churna*Group (Group B).

So, analysing the data obtained from the present study, the null hypothesisi.e., *Virechana*followed by *Vasadi Churna*isnot effective than that of V*asadi Churna*alone in the managementof *Asrigdara*(AUB)) has rejected and the alternate hypothesisi.e., *Virechana*followed by *Vasadi Churna*(GroupA) is more effective than *Vasadi Churna*alone (Group B) in themanagement of *Asrigdara* (AUB)) has accepted.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-05-03
• Study Completion: 2021-05-20
• Last Update Posted: 2021-06-27

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 40

Inclusion Criteria

Patients having any one or two of the following features will be included Ayurvedic features of Asrigdara Modern features Excessive bleeding Prolonged duration Intermenstrual bleeding Bleedinng due to other cause Patients who are Yogya for Virechana The quantity of bleeding will be decided by complete soaked number of pads and using thickened pads.

Exclusion Criteria

Age below 18 and above 50 years Bleeding due to Erosion cancer fibroid and Polyp Bleeding followed by abortion Bleeding from the site other than the uterus Coagulation disorders Suffering from malignancies and chronic systemic diseases like, uncontrolled hypertension (Systolic blood pressure above 180 & Diastolic blood pressure above 120mmhg) uncontrolled diabetes (above the range of 160-200 mg/dl (RBS) Veneral disease Patients who are Ayogya for Virechana Post menopausal bleeding Hb% <7.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
cure of asrigdara	4 month

Secondary Outcome Measures

Name	Time	Method
Relief in bleeding as compare to previous	4 month

Trial Locations

Locations (1)

IPGT AND RA PG HOSPITAL; 🇮🇳 Jamnagar, GUJARAT, India

IPGT AND RA PG HOSPITAL

🇮🇳Jamnagar, GUJARAT, India

ANKIT KUMAR GARG

Principal investigator

8302463471

drankitgarg111@gmail.com